| This week's sponsor is Kaiser Associates. | | | |
Today's Rundown Midstage success prompts Arena to push bowel disease drug etrasimod into phase 3 Kerrisdale targets Proteostasis’ ‘ineffective’ cystic fibrosis drug in latest short attack Medicxi founds biotech creation engine C21Med [Sponsored] Digital R&D: Emerging technologies can boost clinical development Ocugen preps dry eye disease drug for phase 3 Anti-aging outfit Unity bags $55M and looks to the clinic Anti-flu drug exploits weakness in H3N2 strain Ex-IQVIA executive takes the reins at patient recruitment specialist Clinerion Featured Story | | | Monday, March 19, 2018 Topline data show that Arena Pharmaceuticals' ulcerative colitis candidate, etrasimod, beat out placebo in a phase 2 trial, giving it the confidence to move into phase 3. |
|
|
| This week's sponsor is NYCEDC. | | | |
Top Stories Tuesday, March 20, 2018 Kerrisdale Capital has fixed on cystic fibrosis biotech Proteostasis Therapeutics in its latest attack. The short seller launched the assault after seeing shares in Proteostasis rise 200% in three months on the back of data from a small midphase trial and the receipt of an FDA breakthrough tag. Tuesday, March 20, 2018 Medicxi has created an “ideas factory” to boost its capacity to turn early-stage science into pipelines of drug candidates and startups to develop them. The VC fund is setting up the venture with its CSO, David Grainger, Ph.D., and Johnson & Johnson’s Richard Mason. Monday, March 19, 2018 Clinical development has fallen behind in adopting digital technologies. While digital transformation can be a complex undertaking, the rewards are well worth the effort. The time for biopharma R&D to act is now. Learn more. Tuesday, March 20, 2018 Eye disease specialist Ocugen remains on course to have two drugs in late-stage testing before the end of the year as its dry eye disease candidate OCU310 clears a phase 2 trial. Tuesday, March 20, 2018 Unity Biotechnologies, which focuses on eliminating senescent cells to treat age-related diseases, will use the new funds to take its osteoarthritis drug into the clinic. Monday, March 19, 2018 A research team led by the University of California at San Diego has developed a small molecule that they believe could weaken or even stop the virulent H3N2 strain of flu in its tracks. It works by exploiting a flaw in the mechanism the virus uses to replicate. Tuesday, March 20, 2018 Clinical trial patient recruitment expert Clinerion has been on a network expansion spree recently, and it has just tapped a new CEO with big CRO experience to help build its global patient access from 180 million to 310 million by the end of this year. Resources Sponsored by: Seton Hall Law 4-day interactive educational program trusted by multi-national companies as part of their compliance training for employees. Explore legal, regulatory and ethical issues faced by pharmaceutical, biotech and medical device manufacturers operating globally. Visit event homepage for session topics. Sponsored by: Reprints Desk The competitive landscape in medical device R&D is tough. And simply investing in R&D is no guarantee for profitability. So how do you accelerate time-to-market? Sponsored by: MK&A There’s no magic bullet to successful access but insights from patient advocates and industry experts can help shape future strategies. Learn how in this webinar. Sign up now! Sponsored by: RBC Wealth Management Employee stock option trading & administration, Restricted stock transactions (Rule 144), Affiliated trading plans (10b5-1), Directed share plans, Equity comp plan administration — private to public Sponsored by: WCG Selecting the right sites to conduct your clinical trials will determine the success or failure of meeting your enrollment goals. Presented by: Covance Global clinical trials are the trend and gaining in popularity, but running a global trial is not a straightforward process. This white paper explores some of the challenges associated with global clinical trials and considerations for ensuring that the collected data comply with the trial's overall objectives. Presented by: Charles River Join us as we discuss how Charles River Celsis® helped Labor L+S AG validate a 7-day membrane filtration sterility test using existing protocols. Presented by: Catalent Learn how Catalent Biologics is paving the way for flexible biologics development and manufacturing through advanced technologies and fully integrated multi-product facility. Presented by: Catalent Download the eBook to get articles from various Elsevier journals highlighting developments in ADC technology. Presented by: Catalent Learn how cell development and process scale-up can be optimized for antibodies requiring additional processing. Sponsored by: RTI Health Solutions In this webinar, we will introduce the rapidly-evolving within-subject clinical trial (WSCT) methods for early phase evidence generation that require fewer people, less time, and usually less funding than traditional early phase methods. Drug Approval, Manufacturing Quality & Regulation 2018 | Online BioBasics: Biotech for the Non-Scientist March 29-30, 2018 | Boston, MA Understanding Drug Pricing and Reimbursement April 3,2018 | Washington, DC IRT Europe – Interactive Response Technologies in Clinical Trials April 10th-11th, 2018 | Brussels, Belgium Field Service USA 2018 April 17-April 20, 2018 | JW Marriott Palm Desert Resort & Spa, CA
Drug Development Immersion April 25-26, 2018 | New York City Biotech for the Non-Scientist May 2-3, 2018 | San Diego, CA MIXiii-Biomed 2018 May 15-17, 2018 | Tel-Aviv, Israel BIO International Convention June 4-7, 2018 | Boston, MA
Drug Development Boot Camp® 2018 November 14-15, 2018 | Boston, MA | Register and start preparing Today! | 